Drug intelligence / Profile preview

TRTL-107

Development stage: Preclinical
Lead developer: Tortugas Neuroscience
Modality: Small Molecules

Overview

TRTL-107 is a small molecule drug candidate being developed by Tortugas Neuroscience for the treatment of schizophrenia. It acts as a partial agonist at the dopamine D2 and D3 receptors and as an antagonist at the serotonin 5-HT2A receptor. This pharmacological profile is designed to modulate dopaminergic and serotonergic signaling, which are key pathways implicated in the pathophysiology of schizophrenia. By acting as a partial agonist at dopamine receptors, TRTL-107 aims to stabilize dopamine levels, potentially reducing positive symptoms while avoiding the side effects associated with complete dopamine blockade. The drug is currently in the preclinical stage of development.

Targets

CLPP (Caseinolytic mitochondrial matrix peptidase proteolytic subunit)

Beyond the preview

Go deeper on TRTL-107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRTL-107.

Explore the full profile